Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver (Q39405429)

11 September 2017

Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver (English)

1 reference

11 September 2017

0 references

0 references

Yueli Tian

1

1 reference

11 September 2017

Jingting Ma

2

1 reference

11 September 2017

Wudong Wang

3

1 reference

11 September 2017

Lingjuan Zhang

4

1 reference

11 September 2017

Jia Xu

5

1 reference

11 September 2017

Kai Wang

6

1 reference

11 September 2017

Dongfu Li

7

1 reference

11 September 2017

language of work or name

1 reference

9 September 2016

1 reference

Molecular and Cellular Biochemistry

11 September 2017

1 reference

11 September 2017

422

1 reference

11 September 2017

75-84

1 reference

11 September 2017

1-2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11010-016-2807-x

11 September 2017

0 references

cites work

Current concepts in the pathogenesis of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

NF-κB, inflammation, and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

SREBP-1c overactivates ROS-mediated hepatic NF-κB inflammatory pathway in dairy cows with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

NEFAs activate the oxidative stress-mediated NF-κB signaling pathway to induce inflammatory response in calf hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol addiction: to die or not to die.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Isolation of mouse hepatocytes for transplantation: a comparison between antegrade and retrograde liver perfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Non-esterified fatty acids activate the AMP-activated protein kinase signaling pathway to regulate lipid metabolism in bovine hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

AMP-activated protein kinase signaling in metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

The Emerging Role of Sirtuin 1 in Cellular Metabolism, Diabetes Mellitus, Diabetic Kidney Disease and Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Inflammatory links between obesity and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Cidea promotes hepatic steatosis by sensing dietary fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol improves health and survival of mice on a high-calorie diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-016-2807-X

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial

21 January 2018

1 reference

12 December 2020

Mouse liver cell culture. I. Hepatocyte isolation

1 reference

12 December 2020

Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease

1 reference

12 December 2020

Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease

1 reference

12 December 2020

Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats

1 reference

12 December 2020

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

1 reference

12 December 2020

Molecular mediators of hepatic steatosis and liver injury

1 reference

12 December 2020

10.1007/S11010-016-2807-X

Identifiers

DOI

1 reference

11 September 2017

1 reference